Dianthus Therapeutics, Inc. /DE/ (DNTH) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -217.84M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 175.60M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-217.84M | (m) | (m) | $175.60M | (m) | (m) |
| 2026-03-31 | $-191.29M | (m) | (m) | $153.16M | (m) | (m) |
| 2025-12-31 | $-177.93M | $2.04M | (m) | $145.64M | (m) | -8739.34% |
| 2025-09-30 | $-140.31M | $3.08M | (m) | $116.95M | (m) | -4558.41% |
| 2025-06-30 | $-129.92M | $4.85M | (m) | $105.21M | (m) | -2676.56% |
| 2025-03-31 | $-117.20M | $6.52M | (m) | $97.03M | (m) | -1796.40% |
| 2024-12-31 | $-101.86M | $6.24M | (m) | $83.11M | (m) | -1633.74% |
| 2024-09-30 | $-82.90M | (m) | (m) | $65.47M | (m) | (m) |
| 2024-06-30 | $-68.76M | (m) | (m) | $47.89M | (m) | (m) |
| 2024-03-31 | $-58.34M | (m) | (m) | $40.07M | (m) | (m) |
| 2023-12-31 | $-48.17M | (m) | (m) | $32.84M | (m) | (m) |
| 2023-09-30 | $-97.11M | (m) | (m) | $59.65M | (m) | (m) |
| 2023-06-30 | $-78.49M | (m) | (m) | $35.13M | (m) | (m) |
| 2023-03-31 | $-89.20M | (m) | (m) | $46.59M | (m) | (m) |
| 2022-12-31 | $-80.90M | (m) | (m) | $55.14M | (m) | (m) |
| 2022-09-30 | $-79.31M | (m) | (m) | $52.47M | (m) | (m) |
| 2022-06-30 | $-80.30M | (m) | (m) | $52.06M | (m) | (m) |
| 2022-03-31 | $-79.83M | (m) | (m) | $51.59M | (m) | (m) |
| 2021-12-31 | $-74.69M | (m) | (m) | $46.77M | (m) | (m) |
| 2021-09-30 | $-73.62M | (m) | (m) | $45.91M | (m) | (m) |
| 2021-06-30 | $-73.75M | (m) | (m) | $46.90M | (m) | (m) |
| 2021-03-31 | $-76.16M | (m) | (m) | $48.38M | (m) | (m) |
| 2020-12-31 | $-78.70M | (m) | (m) | $50.62M | (m) | (m) |
| 2020-09-30 | $-84.27M | $0.00 | (m) | $57.07M | (m) | (m) |
| 2020-06-30 | $-88.54M | $0.00 | (m) | $61.81M | (m) | (m) |
| 2020-03-31 | $-87.86M | $0.00 | (m) | $62.63M | (m) | (m) |
| 2019-12-31 | $-82.97M | $0.00 | (m) | $59.21M | (m) | (m) |
| 2019-09-30 | $-76.26M | $0.00 | (m) | $52.88M | (m) | (m) |
| 2019-06-30 | $-70.32M | $0.00 | (m) | $47.78M | (m) | (m) |
| 2019-03-31 | $-65.01M | $0.00 | (m) | $44.03M | (m) | (m) |
| 2018-12-31 | $-59.96M | $0.00 | (m) | $41.34M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-42.22M | $0.00 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-35.73M | $0.00 | (m) | $27.90M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-9.27M | $0.00 | (m) | $5.78M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |